Dr. Beth Faiman Shares Insights From Her Myeloma Presentations at ASH 2024

Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, of the Cleveland Clinic Taussig Cancer Institute in Ohio, joined Cancer Nursing Today at the 2024 American Society of Hematology Annual Meeting and Exposition to discuss her multiple myeloma research.

She presented multiple abstracts at the meeting, one of which focused on patient experiences with talquetamab, which is a GPRC5D-targeting bispecific antibody for myeloma.

“I think that it's an especially important role for nurses, advanced practitioners, and physicians alike to let patients know what to experience, give them suggestions for side effect management,” Dr. Faiman said.

Advertisement

Latest News

Advertisement
Advertisement
Our Contributors

Expert Interviews

Conference Highlights

Cecilia BrownConferences | December 13, 2024
An ASH 2024 presentation of data from the Myelofibrosis and Essential Thrombocythemia Observational Study provided insights.
Read More
Katie KoskoGVHD | December 13, 2024
The study highlighted that adding abatacept to CNI/MTX-based GVHD prophylaxis showed durable central outcomes post-HCT.
Katie KoskoConferences | December 13, 2024
Risk factors for GVHD and its severity differ by donor type following allogeneic SCT with post-transplant PTCy prophylaxis.
Katie KoskoGVHD | December 13, 2024
Patients with pulmonary comorbidities and a history of smoking are at increased risk for chronic GVHD.

Network Websites